Corpus Intelligence IC Memo — ROBERT WOOD JOHNSON UNIVERSITY HOSPI 2026-04-26 14:13 UTC
IC Memo — ROBERT WOOD JOHNSON UNIVERSITY HOSPI
Investment Committee Memorandum | NJ | 639 beds | Grade B | EBITDA uplift $103.8M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ROBERT WOOD JOHNSON UNIVERSITY HOSPI

CCN 310038 | MIDDLESEX, NJ | 639 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

ROBERT WOOD JOHNSON UNIVERSITY HOSPI is a 639-bed large academic medical center in MIDDLESEX, NJ with $1.41B in net patient revenue and a -4.0% operating margin. The hospital serves a payer mix of 25.5% Medicare, 5.4% Medicaid, and 69.0% commercial.

Thesis: Undervalued. Our ML models identify $103.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -4.0% to 3.3% (+736bps).

Net Revenue HCRIS$1.41B
Current EBITDA COMPUTED$-56.7M
Operating Margin COMPUTED-4.0%
Occupancy HCRIS89.6%
Revenue / Bed COMPUTED$2.2M
Net-to-Gross HCRIS20.4%
Distress Probability ML38.6%

2. Market Context & Competitive Position

95
NJ Hospitals
-3.9%
State Median Margin
22
Comparable Hospitals

NJ has 95 Medicare-certified hospitals with a median operating margin of -3.9%. The target's margin of -4.0% places it below the state median. Among 22 size-comparable peers (320-1278 beds), the median margin is -4.1%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (320-1278), prioritizing same-state peers. 22 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ROBERT WOOD JOHNSON UNIVERSITY (Target)NJ639$1.41B-4.0%
HACKENSACK UNIVERSITY MEDICAL NJ779$2.00B-2.5%
MORRISTOWN MEDICAL CENTERNJ705$1.70B10.3%
COOPER UNIVERSITY HOSPITALNJ580$1.43B2.0%
JERSEY SHORE UNIVERSITY MED CTNJ604$1.17B8.4%
COOPERMAN BARNABAS MEDICAL CENNJ554$1.07B-4.3%
WEST JERSEY HEALTH SYSTEMNJ587$958.4M7.1%
THE VALLEY HOSPITALNJ385$951.8M17.5%
OVERLOOK MEDICAL CENTERNJ440$880.2M8.9%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $103.8M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$29.6M+210bp18mo
Cost to Collect4.5%2.5%$28.2M+200bp12mo
Denial Rate Reduction12.0%6.5%$27.9M+198bp12mo
A/R Days Reduction5200.0%3800.0%$17.2M+122bp9mo
Clean Claim Rate88.0%96.0%$903K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$29.6M
Cost to Collect
$28.2M
Denial Rate Reduction
$27.9M
A/R Days Reduction
$17.2M
Clean Claim Rate
$903K
Total EBITDA Uplift$103.8M
Current EBITDA$-56.7M
+ RCM Uplift+$103.8M
Pro Forma EBITDA$47.1M
Current Margin-4.0%
Pro Forma Margin3.3%
WC Released (1x)$54.1M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-87.3M$664.2M0.00x-100.0%
Base (11x exit)10.0x11.0x$-87.3M$702.3M0.00x-100.0%
Bull Case9.0x11.0x$-78.6M$1.02B0.00x-100.0%
Bull (12x exit)9.0x12.0x$-78.6M$1.09B0.00x-100.0%
Bear Case11.0x10.0x$-96.0M$173.3M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-96.0M$159.5M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 22 hospitals with 320-1278 beds
  • Same-state prioritization (n=23)
  • Comp margins: P25=-9.1% / P50=-4.1% / P75=5.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.